INTRODUCTION
============

Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) has been defined as a condition characterized by several features of asthma and COPD by the Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) committees in 2014. COPD is characterized by irreversible airflow limitation associated with aging and smoking, whereas asthma is characterized by reversible airflow limitation associated with atopic features.[@B1][@B2][@B3] Asthma is a completely different disease from COPD in its pathophysiology;[@B4] Therefore, many studies have reported that ACOS is a distinct phenotype of COPD.[@B5][@B6][@B7] However, there has been no consensus regarding how different ACOS is from COPD in its clinical characteristics and prognosis. Many studies have reported that patients with ACOS have more severe respiratory symptoms, a more greatly impaired quality of life, more frequent exacerbations, and more comorbidities compared with patients with COPD.[@B8][@B9][@B10] However, some studies have reported no significant difference between them.[@B5] Moreover, other recent studies reported that patients with ACOS had better prognoses, including mortality and lung function.[@B11][@B12]

The aim of this study was to determine whether the clinical characteristics and prognoses of patients with asthma-COPD overlap (ACO) which indicates a generous term of ACOS defined by Barnes[@B9] and the 2017 GINA guideline[@B13] differ from those of patients with pure COPD.

MATERIALS AND METHODS
=====================

Data collection
---------------

We analyzed data from a Korean COPD Subtype Study (KOCOSS) cohort collected from 45 study centers throughout Korea.[@B14] Recruitment, enrollment, and measurement occurred between December 2011 and October 2016. Enrollment criteria for the KOCOSS cohort were Korean adults ≥40 years old with a post-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) value \<0.7 at any clinical visit. Exclusion criteria were subjects who (1) could not perform the pulmonary function test, (2) used systemic steroids because of other underlying diseases, and (3) could not communicate with clinicians. Smoking history and status, respiratory symptoms including coughing and sputum, and comorbidities were assessed at the first visit. All data were collected by trained nurses, and patients were followed up at 6-month regular intervals. A pulmonary function test was performed for all subjects and blood sampling was performed at the first visit. The total immunoglobulin E (IgE) level and absolute eosinophil count were analyzed from the obtained blood samples.

Patient selection by COPD and ACO definitions
---------------------------------------------

Among the 1,675 patients enrolled in the KOCOSS cohort, 1,504 were diagnosed with COPD based on a pulmonary function test with a post-BD FEV1/FVC \<0.7 at the first visit. The occurrence of ACO was defined as a positive response to a BD (an increase in FEV1 of 12% and 200 mL). Then, 1,281 patients were diagnosed with "pure" COPD and 223 patients were diagnosed with ACO ([Fig. 1](#F1){ref-type="fig"}).

Among them, 834 were followed up for more than 2 years and analyzed to define exacerbation rate for 2 years. Additionally 189 patients were followed up with pulmonary function tests at 1-year intervals for more than 3 years and analyzed to define change in lung function for 3 years.

COPD assessment test (CAT) and St. George Respiratory Questionnaire scores
--------------------------------------------------------------------------

The CAT score and St. George Respiratory Questionnaire for COPD patients (SGRQ-C) score were used to assess health status in patients with COPD. The CAT consists of 8 items and includes questions on symptoms, energy, sleep, and activity. A higher score indicates more severe symptoms.[@B15] The SGRQ-C includes 40 items and contains 3 parts scoring symptoms, activities, and impacts on daily life. Total and component scores were calculated according to algorithms provided in the SGRQ-C instruction manual. A higher score means a poorer quality of life.[@B16]

Exacerbation definition
-----------------------

Exacerbation was defined as the worsening of any respiratory symptom, such as increased sputum volume, purulence, or increased dyspnea, which required treatment with systemic corticosteroids, antibiotics, or both. Exacerbation history in the previous 12 months was assessed at the first visit, the 1-year follow-up visit, and the 2-year follow-up visit.

Statistical analysis
--------------------

For continuous variables, descriptive statistics are reported as means with standard deviations (SDs), and for categorical variables as the number of patients per category and the frequency of responses. Comparisons of continuous variables were made using the 2-sample *t* test; the χ^2^ test or Fisher\'s exact test were used for comparisons of categorical variables. Comparisons of FEV1 changes over time were assessed with a repeated analysis of variance (ANOVA). Differences were considered statistically significant at *P*\<0.05.

Ethics statement
----------------

The protocol was approved by the Institutional Review Board at each center. All patients provided written informed consent for participation in the study.

RESULTS
=======

Comparisons of demographics and clinical characteristics between the pure COPD and ACO group
--------------------------------------------------------------------------------------------

Among 1,504 patients with COPD, 223 (14.8%) were diagnosed with ACO after presenting a bronchodilator response (BDR). The pure COPD group had more women (9.5%) than the ACO group (4.5%; *P*=0.015). The ACO group had more current smokers (32.9%) than the pure COPD group (25.3%; *P*=0.026). Although the prevalences of coughing and sputum were not different between the 2 groups, patients with ACO reported a better quality of life (SGRQ-C score=31.0±18.0 \[mean±standard deviation\]) than those with pure COPD (35.3±19.1) (*P*=0.002). There was no significant difference in lung function or comorbidities between the 2 groups ([Table 1](#T1){ref-type="table"}). Although the data are not shown, the prevalence of a treatment-naïve status (7.7% and 11.6%), mean duration of treatment for COPD (5.3±5.3 and 4.9±4.6 years), or prevalence of a history of inhaled corticosteroids (ICS) use (83.1% and 82.5%) was not significantly different between the COPD and ACO groups.

Comparisons of prognoses between the COPD and ACO groups
--------------------------------------------------------

Among all the patients, 834 (55.4%) were followed up for more than 2 years. At baseline, 27.5% of pure COPD subjects and 20.3% of ACO subjects experienced an acute exacerbation in the previous year (*P*=0.086). After 1 year, 20.9% of pure COPD subjects and 18.0% of ACO subjects responded that they had an acute exacerbation in the previous year (*P*=0.461). After 2 years, 19.7% of the pure COPD subjects and 14.3% of the ACO subjects experienced an acute exacerbation in the previous year (*P*=0.144). Pure COPD subjects showed more frequent acute exacerbations than did ACO subjects; however, there was no statistically significant difference ([Fig. 2A](#F2){ref-type="fig"}).

Among the 834 patients with more than 2 years of follow-up data, 12.7% of pure COPD subjects and 8.3% of ACO subjects experienced severe acute exacerbations requiring hospital admission in the previous year at baseline (*P*=0.150). In the results obtained after the first year, pure COPD subjects more frequently had severe acute exacerbations requiring hospital admission (5.5%) in the previous year than ACO subjects (1.5%; *P*=0.030). In the results from after the second year, the same findings were observed (5.6% vs 0.8%; *P*=0.015) ([Fig. 2B](#F2){ref-type="fig"}). Among pure COPD subjects with acute exacerbations, 26.5% were admitted to the hospital. ACO subjects were admitted less frequently (16.7%); however, there was no significant difference (*P*=0.051) ([Fig. 2C](#F2){ref-type="fig"}).

Among all patients, 189 were followed up for more than 3 years and underwent pulmonary function tests at 1-year intervals. ACO subjects tended to recover pulmonary function over time (predicted FEV1: 50.2% at baseline; 58.3% after 1 year; 57.6% after 2 years; and 59.1% after 3 years). However, pulmonary function was not recovered in pure COPD subjects (predicted FEV1: 54.1% at baseline; 55.9% after 1 year; 56.0% after 2 years; and 53.8% after 3 years). The difference in this trend was statistically significant between the 2 groups (*P*\<0.001) ([Fig. 3A](#F3){ref-type="fig"}). Moreover, the changes in absolute FEV1 showed the same results as those for predicted FEV1 (*P*\<0.001) ([Fig. 3B](#F3){ref-type="fig"}).

Predictive power of the AEC for ACO
-----------------------------------

We attempted to find predictive variables for ACO. Levels of IgE (number of included patients, 265; odds ratio \[OR\], 0.999; *P*=0.177), history of asthma (number of included patients, 1,477; OR, 1.152; *P*=0.334), and history of allergic rhinitis (number of patients included, 1,475; OR, 1.107; *P*=0.662) were not significant predictive factors. However, the AEC was a significant predictive factor for ACO (number of patients included, 1,199). We analyzed the predictive power of the AEC for ACO according to various AEC cutoff values. When we used ≥200/µL as a cutoff value, the OR was 1.580 (95% confidence interval, 1.150-2.17; *P*=0.005). The sensitivity and specificity were 51.4% and 59.9%, respectively (*P*=0.015). When we used a cutoff value of ≥250/µL, the OR was significant, whereas the sensitivity and specificity were not significantly predictive. The results from a cutoff value of ≥300/µL were not significantly predictive. Although the results from a cutoff value of ≥500/µL were not significantly predictive, the specificity was the highest (90.3%) ([Table 2](#T2){ref-type="table"}).

DISCUSSION
==========

There are many studies showing that ACO had a poor prognosis compared with pure COPD. However, this cohort study determined that ACO is a distinct phenotype of COPD representing better clinical outcomes. First, we observed that patients with ACO had the possibility of recovering their lung function. In fact, the baseline lung function at the first visit was poorer in patients with ACO than that in those with COPD in this cohort study. However, the decline in lung function was more remarkable in patients with pure COPD than those with ACO in this cohort study. Some cross-sectional studies reported that patients with ACO demonstrated poorer lung function than those with pure COPD.[@B17] However, Kauppi et al.[@B18] reported that the post-BD FEV1 was significantly better in ACO (67.4%) than in pure COPD (61.4%). In addition, De Marco et al.[@B11] showed a rapid decline in FEV1 in pure COPD (-7.64 mL/year) in contrast to an improvement in FEV1 in ACO (1.62 mL/year), which is consistent with our result. The recovery of lung function in ACO might be due to an asthma component with a good response to ICS treatment. Thus, we suggest that the possibility of recovering lung function may be the same characteristics of ACO compared as pure COPD.

Second, we revealed that the severe exacerbation rate was lower in ACO compared with pure COPD. Some studies reported that the exacerbation rate was higher in ACO than in COPD.[@B5][@B10] This cohort study showed similar total exacerbation rates between ACO and pure COPD. However, we showed that severe exacerbation requiring hospital admission was more frequent among patients with pure COPD. This result may be associated with the results of the previous studies which described that patients with COPD had a lower chance of recovering lung function. Izquierdo-Alonso et al.[@B19] previously showed that the exacerbation rate was lower in ACO (64.9%) compared with COPD of the emphysema type (68.8%). In addition, they showed that the number of visits to the emergency department was slightly lower in ACO (0.79/year) compared with COPD of the emphysema type (1.12/year) and COPD of the bronchitis type (1.25/year); however, the difference was not statistically significant. The higher survival rate among ACO patients was confirmed by Cosio et al.[@B12] and this may be understood in the same context as in this cohort study. Further studies are needed to differentiate severe exacerbation rates between ACO and COPD.

Finally we showed that the symptoms were better in ACO compared pure COPD. Many studies reported that symptoms and quality of life were worse in ACO compared with pure COPD.[@B8][@B18][@B20][@B21] Some studies showed that symptoms and quality of life in ACO were not different from those in COPD.[@B5] It was difficult to find studies showing better symptoms in ACO, in concordance with this cohort study. Although data are not shown, SGRQ-C was significantly correlated with exacerbation rate and lung function recovery. Multivariate analysis showed that ACO was a dependent prognostic factor on SGRQ-C for exacerbation and lung function recovery. Then, we can suggest that subjects with ACO have less severe symptoms, and therefore it might lead to rare severe exacerbation, and the possibility of lung function recovery.

The result that ACO showed better clinical outcomes than pure COPD in this cohort study is in contrast to major opinions supported by extensive studies. The main reason is due to the differences in study design. This cohort study included treatment-naïve and ICS-naïve subjects. Moreover, the mean treatment duration was relatively short (4-5 years) compared with those in other studies (usually more than 10 years). These might have caused ACO to show better clinical outcomes after enrollment in the cohort study followed by proper ACO management. Another reason is due to the unique asthma characteristics in Korea. Asthma is diagnosed and managed mainly in primary care. In Korea, the prevalence of asthma is estimated to be about 3%-5%, whereas it is thought to be 8%-20% in other countries. Many Korean asthmatic patients do not use ICS treatment properly (the treatment rate is lower than 50%), especially in primary care.[@B22] Moreover, the asthma fatality rate per 100,000 asthmatics is 7%-9% in Korea, whereas it is less than 5% in most countries. This means that many primary clinics missed the diagnosis of asthma, and even physician-diagnosed asthma patients do not use their treatment drug properly. These unique asthma characteristics in Korea might have induced the ACO subjects to have a lesser opportunity to treat their asthma properly prior to enrollment, and finally, their prognoses improved after enrollment in the cohort study which consisted of pateints from second or tertiary hospitals following proper ACO management, including ICS treatment.

ACOS has recently received attention, and the definition of ACOS has not been established. The Spanish criteria,[@B23] modified Spanish criteria,[@B12] and *European Respiratory Journal* (*ERJ*) criteria[@B24] are the most prominent criteria, and require that various items be fulfilled to diagnose ACOS. The Spanish criteria were created in 2012 and include eosinophilia in sputum, a history of atopy, and the level of total IgE. However, in practice, many institutes cannot assess eosinophilia in sputum. The modified Spanish criteria and *ERJ* criteria were created in 2016 and exclude sputum eosinophilia, and instead include blood eosinophilia. However, these criteria still contain 6 items. Many studies have attempted to diagnose ACOS simply and properly;[@B25] however, there is still no consensus. Caillaud et al.[@B5] defined ACOS very simply as follows: a patient enrolled in a COPD cohort study who was diagnosed with asthma by a physician before the age of 40 years. We used very simplified criteria for ACO: the intersection of asthma and COPD, as defined by the 2014 GINA and GOLD guidelines, with a BDR (post-BD FEV1 improvements of 12% and 200 mL).

Some researchers believe that a BDR is not credible to identify the phenotype of COPD, ACO.[@B26] However, there are many studies that used simplified criteria for ACOS as this study did (in the assumptions on COPD). Fu et al.[@B6] (BDR or airway hyper-responsiveness), Menezes et al.[@B17] (BDR and wheezing), Kauppi et al.[@B18] (BDR including PEF and an exercise test), and Contoli et al.[@B27] (BDR and a history of asthma) used relatively simple criteria, including BDR and/or other simple conditions. Recently, Baarnes et al.[@B28] showed similar characteristics in ACOS defined by wheezing, BDR, or both, and they concluded that ACOS could be identified only by BDR as in this cohort study. In addition, considering the prevalence of ACOS among COPD, which is 15%-25% as defined by various criteria,[@B5][@B29][@B30][@B31] the prevalence of ACOS in this study (14.8%) indicates that the definition used in this study does not differ substantially from the more complicated classic criteria previously described. Thus, we thought that the simplified criteria for ACOS used in this study could be applied. However, some researchers still have questions whether COPD with mild BDR is sufficient to define ACOS. Barnes[@B9] described that ACO is better to include the various phenotypes of status with features of COPD and asthma: COPD with mild BDR, COPD with eosinophilic inflammation, asthma with smoking history, and asthma with neutrophilic inflammation. Furthermore,the 2017 GINA guideline also used the term of ACO.[@B13] Then, we used the term of ACO described by Barnes and the 2017 GINA guideline rather than ACOS to avoid controversy.

When we attempted to find predictive variables for ACO, blood eosinophil count was significantly superior to the level of total IgE, history of asthma, and history of allergic rhinitis. Moreover, the most powerful cutoff value for eosinophil count was 200/µL. The modified Spanish criteria and *ERJ* criteria contain a history of asthma as a major criterion, whereas they include blood eosinophil count as a minor criterion; the cutoff values for blood eosinophilia were 5% and 300/µL in the modified Spanish criteria and *ERJ* criteria, respectively. We suggest that the blood eosinophil count will be a better predictive marker for ACO than expected. Additionally, the adjusted cutoff value for blood eosinophilia can be applied to stronger predictive power in ACO.

This study has several limitations. First, ACO as defined in this study might not be the correct definition of ACO. Additionally, we could not apply the definition previously described (GINA and GOLD guidelines, Spanish criteria, modified Spanish criteria, and *ERJ* criteria), as this cohort study did not contain all the parameters described in those criteria. Second, only 50% and 13% of subjects were followed up for 2 years and 3 years, respectively, and they were analyzed for exacerbation and lung function. Almost all excluded patients in the follow-up study were recently enrolled patients in the cohort study. However, we cannot exclude a selection bias in which subjects who were more compliant might have been enrolled in larger numbers in the follow-up study. Third, there were some missing values for the level of total IgE, blood eosinophil count, history of asthma, and history of allergic rhinitis. Moreover, a history of asthma should be changed to a history of asthma before the age of 40 years for better evaluation. Finally we cannot fully exclude the possibility of selection bias. The results that ACO patients showed less symptoms might be brought about by selection bias. KOCOSS cohort data were collected from 45 institutions across the country for 5 years. The recruitment and enrollment of subjects are still ongoing, and it is necessary to review the results of the re-analysis of the long-term follow-up data.

This COPD cohort study defined ACO (14.8%), which is a distinct type of COPD. We suggest that subjects with ACO have less severe symptoms, and therefore it might lead to rare severe exacerbation and the possibility of lung function recovery. Moreover, blood eosinophil count (≥200/µL) could be a suitable predictive factor for ACO.
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###### Comparison of demographics and clinical characteristics between COPD and ACO

![](aair-9-431-i001)

  Characteristics      COPD (n=1,281)   ACO (n=223)   *P* value
  -------------------- ---------------- ------------- -----------
  Demographics                                        
   Female              121 (9.5)        10 (4.5)      0.015
   Age                 71.6±7.7         71.0±7.7      0.285
   Pack-year           44.0±25.5        45.1±24.9     0.584
   Current smoker      323 (25.3)       73 (32.9)     0.026
   BMI                 22.7±3.4         23.2±3.3      0.058
  Symptoms                                            
   Cough               308 (24.3)       55 (24.9)     0.859
   Sputum              403 (32.0)       80 (36.4)     0.198
   CAT                 15.9±7.9         15.1±7.8      0.172
   SGRQ                35.3±19.1        31.0±18.0     0.002
  Lung function                                       
   FEV1%               55.1±17.9        52.7±14.5     0.051
   FVC%                80.6±17.5        81.1±17.6     0.693
   FEV1/FVC            48.2±12.1        46.6±9.5      0.055
  Comorbidity                                         
   HTN                 496 (39.1)       72 (32.7)     0.074
   DM                  213 (16.8)       28 (12.7)     0.131
   MI                  66 (5.3)         7 (3.2)       0.191
   HF                  46 (3.7)         6 (2.7)       0.497
   Hyperlipidemia      135 (10.8)       16 (7.3)      0.118
   Allergic rhinitis   131 (10.4)       25 (11.4)     0.662
   Atopic dermatitis   39 (3.1)         5 (2.3)       0.518

Data are shown as mean ± standard deviation or number (%).

COPD, chronic obstructive pulmonary disease; ACO, asthma-chronic obstructive pulmonary disease overlap; BMI, body mass index; CAT, chronic obstructive pulmonary disease assessment test; SGRQ, St. George Respiratory Questionnaire; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HTN, hypertension; DM, diabetes mellitus; MI, myocardial infarction; HF, heart failure.

###### Predictive power of AEC for ACO

![](aair-9-431-i002)

  Cut-off value   OR (95% CI)           *P* value   Sensitivity (%)   Specificity (%)   *P* value
  --------------- --------------------- ----------- ----------------- ----------------- -----------
  AEC ≥200        1.580 (1.150-2.170)   0.005       51.4              59.9              0.015
  AEC ≥250        1.448 (1.046-2.004)   0.026       49.6              41.1              0.068
  AEC ≥300        1.313 (0.925-1.866)   0.128       29.3              76.0              0.254
  AEC ≥500        1.284 (0.786-2.100)   0.318       12.2              90.3              0.602

AEC, absolute eosinophil count; ACO, asthma-chronic obstructive pulmonary disease overlap; OR, odds ratio; CI, confidence interval.
